BioPharma Resources

Drug Trial Radar · NCT04843098

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

May 26, 2021

Primary completion

Nov 20, 2024

Study completion Apr 23, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • TL117Drug

    TL117 capsules orally once daily

  • PaclitaxelDrug

    Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatmentTime frame: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
  2. Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatmentTime frame: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
  3. Phase II - Objective response rate (ORR)Time frame: Every 8 weeks from date of first treatment until date of last treatment up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.